Explore factors impacting RA and axSpA management, such as radiographic progression, and sex and gender differences.
Professor Lluís Puig is Director of Dermatology at the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, and Professor of Dermatology at the University of Barcelona, Spain.
For over 15 years, Professor Puig’s clinical research has focused on the treatment of psoriasis with biological agents. He has worked on over 85 clinical trials and research projects, primarily as the principal investigator.
Professor Puig also serves on several editorial boards and has published over 300 papers in journals such as The New England Journal of Medicine, Journal of the European Academy of Dermatology and Venereology, and British Journal of Dermatology.
He is a member of multiple national and international scientific societies, has been a member of the board of directors of the European Academy of Dermatology and Venereology (EADV), and is co-Chair of the Psoriasis Task Force of the EADV, Member of the GRAPPA Education and Steering Committees, and Board Member of the International Psoriasis Council.
Explore factors impacting RA and axSpA management, such as radiographic progression, and sex and gender differences.
Integrating holistic care through guideline recommendations with patient-reported outcomes and shared decision-making
Personalised HS care: Addressing the multi-faceted burden of HS with a case study example
The role of combined medical/surgical and medical-only treatments, including the optimal time for intervention
Key guideline updates including management algorithms for inflammatory and non-inflammatory HS phenotypes
Prof. Prignano and Prof. Liakou discuss patient-reported outcomes, shared decision-making and multidisciplinary HS care